AUTHORS
Andrew D. Leavitt, MD, Danielle Briggs, NP2, Annabel Frank, MD3, Elle Fukui, MD4, Cynthia Fenton5, Roxanna Irani, MD6
AFFILIATIONS
1 University of California San Francisco, San Francisco, California, United States
2 University of California San Francisco, San Francisco, California, United States
3 University of California San Francisco, San Francisco, California, United States
4 University of California San Francisco, San Francisco, California, United States
5 University of California San Francisco, San Francisco, California, United States
6 University of California San Francisco, San Francisco, California, United States
ABSTRACT
Background: Iron deficiency (ID) is common in pregnancy, is associated with adverse maternal, newborn, and early childhood outcomes, but is not reliably detected by CBC indices. Our prior research found that hemoglobin and MCV have low sensitivity to identify 1st-trimester ID. Among women with ID defined by ferritin < 30 ng/ml, 59% had normal hemoglobin and MCV. Current professional guidelines offer mixed recommendations, ranging from CBC screening alone to broader assessment of iron status including ferritin. To address concerns of underdiagnosis and treatment of ID in pregnancy, we implemented universal iron screening across all of our prenatal sites starting in February 2024.
Methods: We identified completed pregnancies among patients who had > 1 first-trimester visits at any UCSF obstetric clinic from January 1, 2022, through December 31, 2025. Automated extraction captured demographics, pregnancy history and outcomes, and laboratory data from the electronic medical record. Data collection continued through July 15, 2026. Screening with CBC and ferritiin was assessed overall, by trimester and by pregnancy using year of 1st-trimester end date. ID was defined as ferritin < 30 ng/mL, with sensitivity analysis using ferritin 50 ng/mL. We assessed the overlap of ID with anemia (hemoglobin < 11 g/dL) and microcytosis (MCV < 80 fL), evaluated the incidence of new ID in each trimester, and compared ID prevalence by race/ethnicity and parity.
Results: There were 8,438 pregnancies among 7,591 patients who met the study criteria. The median age was 34 years at last menstrual period. The cohort was racially and ethnically diverse with 41% white, 28% Asian, 13% Hispanic/Latinx, 6% Black or African American, and 12% other. Among pregnancies with parity data (7,487/8,438), 51% were nulliparous, 36% had parity of 1, and 13% had parity of > 2. CBC testing remained nearly universal, with 1st-trimester CBC performed in 94% of pregnancies annually for 2022-2025. Ferritin screening increased from 25% and 38% (2022-2023) to 86% and 90% (2024-2025) after implementation of our screening program. Among pregnancies with 1st-trimester ferritin, 13% (517/4,008) had ID with ferritin < 30; 32% (1,286/4,008) had ferritin < 50. Among pregnancies with 1st-trimester ferritin < 30 and available CBC data, 90% (449/498) had no anemia, 85% (425/498) had no microcytosis, and 83% (412/498) had neither anemia nor microcytosis. When evaluated by race and ethnicity, the prevalence of 1st-trimester ID (ferritin < 30) was higheset at 22% in Black or African American, followed by 18% in Hispanic/Latinx, 13% in White, 15% in other/unknown, and 8% in Asian (p<0.01). This trend persisted when using ferritin < 50. Among pregnancies with 1st-trimester ferritin > 50, a new low ferritin < 50 was detected in 74% (1,242/1,668) of those retested in the 2nd trimester and 74% (937/1,257) in the 3rd trimester. For pregnancies with a 1st-trimester ferritin 30-49 (743), a ferritin < 30 was observed in 80% (400/502) of those retested in the 2nd trimester and 53% (207/394) who were retested in the 3rd trimester.
Conclusion: In this diverse obstetric cohort at a large academic health system, prospective ferritin screening increased substantially following implementation of a universal obstetric iron screening program, while CBC screening remained nearly universal pre- and post- implementation. Routine prospective ferritin testing found that 1st-trimester ID occcurred in nearly 1 of 7 (ferritin < 30) and 1 of 3 (ferritin < 50) pregnancies. Nearly 3 of 4 patients with a normal 1st-trimester ferritin (> 30) who underwent repeat testing developed ID later in pregnancy. Over 80% of iron-deficient pregnancies would not have been detected by CBC screening due to normal hemoglobin and MCV. Compared with published retrospective cohorts, the higher proportion of pregnancies with ID without anemia or microcytosis likely reflects that historically, ferritin testing was obtained in response to clinical suspicion or abnormal CBC findings. Our data support routine 1st trimester ferritin screening and suggest that repeat testing beyond the 1st trimester may identify a substantial. number of individual who develop incident ID despite a ferritin > 30 in the 1st trimester.
DISCLOSURES
Andrew D. Leavitt, MD: Sanofi - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony)